<DOC>
	<DOCNO>NCT02943070</DOCNO>
	<brief_summary>Evaluate safety efficacy Rezum System treatment BPH</brief_summary>
	<brief_title>Rezum I Pilot Study BPH</brief_title>
	<detailed_description>Prospective , non-randomized clinical trial subject benign prostatic hyperplasia . The objective study 1 ) determine safety efficacy BPH Rezum System assess effect urinary symptom secondary benign prostatic hyperplasia ( BPH ) , 2 ) document safety post-operative effect Rezum System treatment obstructive BPH .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<criteria>1 . Male subject &gt; 45 year age symptomatic / obstructive symptom secondary BPH require invasive intervention . 2 . IPSS score ≥ 15 . 3 . Qmax : Peak flow rate ≤ 15 ml/sec . 4 . Postvoid residual ( PVR ) &lt; 300 ml . 5 . Prostate transverse diameter &gt; 30 mm . 6 . Prostate volume 20 120 gm . 7 . Voided volume ≥ 125 mL 8 . Subject able complete study protocol opinion investigator . 9 . Life expectancy least one year . 1 . History illness surgery may confound result study risk subject . 2 . Presence penile implant . 3 . Any prior minimally invasive intervention ( e.g . TUNA , Balloon , Microwave ) surgical intervention symptom BPH . 4 . Currently enrol enrol another trial past 30 day . 5 . Confirmed suspected malignancy prostate bladder 6 . Previous rectal surgery ( hemorrhoidectomy ) history rectal disease . 7 . Previous pelvic irradiation radical pelvic surgery . 8 . Documented active urinary tract infection culture bacterial prostatitis within last year document culture ( UTI define &gt; 100,000 colony per ml urine midstream clean catch catherization specimen ) 9 . Neurogenic bladder sphincter abnormality . 10 . Urethral stricture , bladder neck contracture muscle spasm . 11 . Bleeding disorder currently coumadin . ( Note use antiplatelet medication exclusion criterion . ) 12 . Subjects interested maintain fertility . 13 . Use concomitant medication include follow : 1 . Use , antihistamine , antispasmodic within 1 week treatment unless document evidence stable dose last 6 month ( dose change ) . 2 . Use alpha blocker , androgen , gonadotropinreleasing hormonal analog within 2 week treatment . 3 . Use 5alpha reductase inhibitor within last 6 month 4 . Use antidepressant , anticholinergic , anticonvulsant , beta blocker unless document evidence stable dose 14 . Subject unable unwilling go `` washout '' period prior treatment . 15 . Subject chronic urinary retention . 16 . Postvoid residual volume &gt; 300 ml . 17 . Significant urge incontinence . 18 . Poor detrusor muscle function . 19 . Neurological disorder might affect bladder sphincter function . 20 . Urinary sphincter abnormality . 21 . Bladder stone . 22 . Evidence bacterial prostatitis symptom epididymitis 23 . Renal impairment serum creatinine &gt; 2.0 mg/dl 24 . In physician 's opinion , subject tolerate cystoscopy procedure well . 25 . Unable unwilling sign Informed Consent Form ( ICF ) and/or comply require followup requirement . 26 . Any cognitive disorder interferes precludes direct accurate communication study investigator regard study . 27 . Peripheral arterial disease intermittent claudication Leriches Syndrome ( i.e. , claudication buttock perineum ) . 28 . Biopsy prostate within 30 day procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rezum</keyword>
	<keyword>Water Vapor Ablation</keyword>
</DOC>